Kamil F. Faridi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kamil F. Faridi has a total of 234 co-authors. Here are the top co-authors by number of shared publications:
Erica S. Spatz
7 shared publicationsHarlan M. Krumholz
Section of Cardiovascular Medicine, Department of Medicine, Yale School of Medicine, New Haven, Connecticut, USA; Center for Outcomes Research and Evaluation, Yale New Haven Health, New Haven, Connecticut, USA
7 shared publications- Mohammed Essa
Richard A. and Susan F. Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center, Boston, MA (M.E.).
7 shared publications - Jeptha P. Curtis
Yale School of Medicine
6 shared publications - Eric A. Secemsky
Harvard Medical School
5 shared publications Huanhuan Yang
Center for Outcomes Research and Evaluation, Yale New Haven Health, New Haven, CT (Y.L., H.Y., E.S.S., H.M.K., K.F.F.).
5 shared publications
Latest Publications
- Open Access
- 19 June 2026
- Published by Elsevier in American Journal of Preventive Cardiology
- Vol. 30
Primary prevention statin eligibility for U.S. adults under the 2026 ACC/AHA dyslipidemia guideline
- 19 June 2026
- Published by Elsevier in American Journal of Preventive Cardiology
- Vol. 30
Open AccessPrimary prevention statin eligibility for U.S. adults under the 2026 ACC/AHA dyslipidemia guideline
- 1 April 2026
- Published by Wolters Kluwer Health in Hypertension
- Vol. 83 (4) , e26387
Primary Prevention Antihypertensive Eligibility With the 2025 AHA/ACC Guideline
- 1 April 2026
- Published by Wolters Kluwer Health in Hypertension
- Vol. 83 (4) , e26387
Primary Prevention Antihypertensive Eligibility With the 2025 AHA/ACC Guideline
- 31 March 2026
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 20 (6) , 1260-1266
Elevated LDL-C and non–HDL-C in U.S. adults with normal total serum cholesterol
- 31 March 2026
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 20 (6) , 1260-1266
Elevated LDL-C and non–HDL-C in U.S. adults with normal total serum cholesterol
- 27 January 2026
- Published by Elsevier in American Heart Journal
- Vol. 295, 107354
Low levels of atherogenic lipoproteins and incident atherosclerotic cardiovascular disease: A pooled cohort primary prevention study
- 27 January 2026
- Published by Elsevier in American Heart Journal
- Vol. 295, 107354
Low levels of atherogenic lipoproteins and incident atherosclerotic cardiovascular disease: A pooled cohort primary prevention study
- Open Access
- 20 January 2026
- Published by Elsevier in JACC: Advances
- Vol. 5 (2) , 102540
Using Machine Learning to Predict Adverse Events in Patients Undergoing Transcatheter Left Atrial Appendage Occlusion
- 20 January 2026
- Published by Elsevier in JACC: Advances
- Vol. 5 (2) , 102540
Open AccessUsing Machine Learning to Predict Adverse Events in Patients Undergoing Transcatheter Left Atrial Appendage Occlusion
- Open Access
- 1 December 2025
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 8 (12) , e2549124
Body Mass Index and Anthropometric Criteria to Assess Obesity
This cross-sectional study estimates US obesity prevalence using newly proposed anthropometric criteria.
- 1 December 2025
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 8 (12) , e2549124
Open AccessBody Mass Index and Anthropometric Criteria to Assess Obesity
This cross-sectional study estimates US obesity prevalence using newly proposed anthropometric criteria.
- Open Access
- 6 August 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (16) , e039780
Long‐Term Outcomes Following Left Atrial Appendage Occlusion in Medicare Beneficiaries: Outcomes From the National Cardiovascular Data Registry
Background: Percutaneous left atrial appendage occlusion (LAAO) is an alternative to long‐term anticoagulation for preventing ischemic stroke in patients with atrial fibrillation. There are limited long‐term outcomes data for “real‐world” patients undergoing LAAO. Methods: We performed a retrospective cohort study using the National Cardiovascular Data Registry LAAO registry from January 1, 2016, through December 31, 2019. We linked LAAO data to inpatient Medicare fee‐for‐service claims data using probabilistic matching to establish a cohort of patients 65 years and older undergoing LAAO with a WATCHMAN device. The primary outcomes were any stroke and all‐cause mortality. Results: A total of 34 975 patients with a mean±SD CHA 2 DS 2 ‐VASc (congestive heart failure, hypertension, age ≥75 years, diabetes, previous stroke or transient ischemic attack, vascular disease, age 65 to 74 years, and sex category) score of 4.7±1.4 were included. The median follow‐up was 2.8 years (interquartile range, 2.2–3.7 years). The cumulative incidence of any stroke was 1.57 per 100 person‐years (95% CI, 1.45–1.70), with a 1‐year and 5‐year any stroke estimate of 1.70% (95% CI, 1.57–1.84%) and 5.70% (95% CI, 5.37–6.05%), respectively. The cumulative incidence of ischemic stroke was 1.36 per 100 person‐years (95% CI, 1.25–1.48), with a 1‐year and 5‐year ischemic stroke estimate of 1.42% (95% CI, 1.30–1.54%) and 5.03% (95% CI, 4.71–5.36%), respectively. The cumulative incidence of death was 10.82 per 100 person‐years (95% CI, 10.49–11.13), with a 5‐year mortality estimate of 44.34% (95% CI, 43.35–45.23%). Conclusions: Long‐term stroke rates in a large nationally representative cohort of Medicare patients following LAAO were low and durably consistent during long‐term follow‐up despite a high thromboembolic risk. High mortality rates in this elderly population underscore the importance of incorporating patient values and preferences when considering LAAO.
- 6 August 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (16) , e039780
Open AccessLong‐Term Outcomes Following Left Atrial Appendage Occlusion in Medicare Beneficiaries: Outcomes From the National Cardiovascular Data Registry
Background: Percutaneous left atrial appendage occlusion (LAAO) is an alternative to long‐term anticoagulation for preventing ischemic stroke in patients with atrial fibrillation. There are limited long‐term outcomes data for “real‐world” patients undergoing LAAO. Methods: We performed a retrospective cohort study using the National Cardiovascular Data Registry LAAO registry from January 1, 2016, through December 31, 2019. We linked LAAO data to inpatient Medicare fee‐for‐service claims data using probabilistic matching to establish a cohort of patients 65 years and older undergoing LAAO with a WATCHMAN device. The primary outcomes were any stroke and all‐cause mortality. Results: A total of 34 975 patients with a mean±SD CHA 2 DS 2 ‐VASc (congestive heart failure, hypertension, age ≥75 years, diabetes, previous stroke or transient ischemic attack, vascular disease, age 65 to 74 years, and sex category) score of 4.7±1.4 were included. The median follow‐up was 2.8 years (interquartile range, 2.2–3.7 years). The cumulative incidence of any stroke was 1.57 per 100 person‐years (95% CI, 1.45–1.70), with a 1‐year and 5‐year any stroke estimate of 1.70% (95% CI, 1.57–1.84%) and 5.70% (95% CI, 5.37–6.05%), respectively. The cumulative incidence of ischemic stroke was 1.36 per 100 person‐years (95% CI, 1.25–1.48), with a 1‐year and 5‐year ischemic stroke estimate of 1.42% (95% CI, 1.30–1.54%) and 5.03% (95% CI, 4.71–5.36%), respectively. The cumulative incidence of death was 10.82 per 100 person‐years (95% CI, 10.49–11.13), with a 5‐year mortality estimate of 44.34% (95% CI, 43.35–45.23%). Conclusions: Long‐term stroke rates in a large nationally representative cohort of Medicare patients following LAAO were low and durably consistent during long‐term follow‐up despite a high thromboembolic risk. High mortality rates in this elderly population underscore the importance of incorporating patient values and preferences when considering LAAO.
- Open Access
- 24 July 2025
- Published by Elsevier in JACC: Advances
- Vol. 4 (8) , 102019
Comparing Claims Data to Stroke and Bleeding in the NCDR Left Atrial Appendage Occlusion Registry
- 24 July 2025
- Published by Elsevier in JACC: Advances
- Vol. 4 (8) , 102019
Open AccessComparing Claims Data to Stroke and Bleeding in the NCDR Left Atrial Appendage Occlusion Registry
- Open Access
- 20 July 2025
- Published by Wiley in The Journal of Clinical Hypertension
- Vol. 27 (7) , e70093
Hypertension Prevalence, Awareness, and Control in US Adults Before and After the COVID‐19 Pandemic
Hypertension is a leading cause of death and disability in the United States, but national trends in hypertension after the COVID‐19 pandemic remain unknown. We analyzed NHANES data from pre‐pandemic (2017–March 2020) and post‐pandemic (August 2021–August 2023) surveys to determine nationwide prevalence, awareness, and control of hypertension. Weighted, age‐standardized prevalence estimates were compared using Poisson regression with prevalence ratios (PRs). Among 14 449 participants representing 237 million US adults, hypertension prevalence was 49.5% pre‐pandemic versus 47.7% post‐pandemic (PR 0.96; p = 0.15). Overall, hypertension awareness was unchanged (57.7% vs. 53.7%; PR 0.96; p = 0.14) but declined among adults aged 18–39 years (PR 0.78; p = 0.02). Blood pressure control remained low (25.9% vs. 22.3%; PR 0.91; p = 0.06) and worsened in men (PR 0.83; p = 0.01). In conclusion, hypertension prevalence, awareness, and control did not significantly improve post‐pandemic. More aggressive public health efforts are needed to reduce the adverse impacts of hypertension in the United States.
- 20 July 2025
- Published by Wiley in The Journal of Clinical Hypertension
- Vol. 27 (7) , e70093
Open AccessHypertension Prevalence, Awareness, and Control in US Adults Before and After the COVID‐19 Pandemic
Hypertension is a leading cause of death and disability in the United States, but national trends in hypertension after the COVID‐19 pandemic remain unknown. We analyzed NHANES data from pre‐pandemic (2017–March 2020) and post‐pandemic (August 2021–August 2023) surveys to determine nationwide prevalence, awareness, and control of hypertension. Weighted, age‐standardized prevalence estimates were compared using Poisson regression with prevalence ratios (PRs). Among 14 449 participants representing 237 million US adults, hypertension prevalence was 49.5% pre‐pandemic versus 47.7% post‐pandemic (PR 0.96; p = 0.15). Overall, hypertension awareness was unchanged (57.7% vs. 53.7%; PR 0.96; p = 0.14) but declined among adults aged 18–39 years (PR 0.78; p = 0.02). Blood pressure control remained low (25.9% vs. 22.3%; PR 0.91; p = 0.06) and worsened in men (PR 0.83; p = 0.01). In conclusion, hypertension prevalence, awareness, and control did not significantly improve post‐pandemic. More aggressive public health efforts are needed to reduce the adverse impacts of hypertension in the United States.